Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 19, 2021 16:01 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Offering of Common Stock

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that it intends to offer and sell 3,500,000 shares of its...
January 11, 2021 06:05 ET | Source: Editas Medicine, Inc.

Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference

Details progress on ocular programs, including EDIT-101 Phase 1/2 BRILLIANCE trial updates Provides EDIT-301 updates, including timeline for dosing sickle cell disease patients in the Phase 1/2 RUBY...
January 11, 2021 06:02 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces the FDA has Cleared Initiation of the EDIT-301 Clinical Trial

CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the U.S. Food and Drug Administration (FDA) has cleared...
January 11, 2021 06:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Transition of Chief Scientific Officer

CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its Chief Scientific Officer, Charles Albright,...
January 04, 2021 16:05 ET | Source: Editas Medicine, Inc.

Editas Medicine to Present at the 39th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview at the 39th...
December 17, 2020 16:05 ET | Source: Editas Medicine, Inc.

Editas Medicine Names Meeta Chatterjee, Ph.D., to Board of Directors

CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it has appointed Meeta Chatterjee, Ph.D., to its...
December 09, 2020 16:01 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Submission of IND Application for EDIT-301 with the FDA

EDIT-301 is in development as a best-in-class, durable medicine for people living with sickle cell disease CAMBRIDGE, Mass., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT),...
December 05, 2020 10:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Preclinical Data and Large-Scale Manufacturing Process for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia

Data support novel approach to develop and manufacture a best-in-class, durable medicine for people living with hemoglobinopathies IND filing for EDIT-301 planned by end of 2020 CAMBRIDGE, Mass.,...
November 10, 2020 16:01 ET | Source: Editas Medicine, Inc.

Editas Medicine Reports Inducement Grants to New Chief Medical Officer

CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company’s newly...
November 09, 2020 16:05 ET | Source: Editas Medicine, Inc.

Editas Medicine to Present at Barclays Gene Editing & Gene Therapy Summit

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will present at Barclays Gene Editing...